Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer

1996 ◽  
Vol 37 (1) ◽  
pp. 57-64 ◽  
Author(s):  
J -Y. Pierga ◽  
A. Leroyer ◽  
P. Viehl ◽  
V. Mosseri ◽  
S. Chevillard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Operable Breast Cancer ◽  
Growth Fraction ◽  
Ki 67 ◽  
Primary Operable Breast Cancer ◽  
Fraction Determination

Long-term prognostic value of PCNA labeling index in primary operable breast cancer.

1998 ◽  
Author(s):  
J Horiguchi ◽  
Y Iino ◽  
H Takei ◽  
M Maemura ◽  
I Takeyoshi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Operable Breast Cancer ◽  
Labeling Index ◽  
Primary Operable Breast Cancer

scholarly journals Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

1993 ◽  
Vol 68 (3) ◽  
pp. 579-583 ◽  
Author(s):  
M Railo ◽  
S Nordling ◽  
K von Boguslawsky ◽  
M Leivonen ◽  
L Kyllönen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Operable Breast Cancer ◽  
Ki 67 ◽  
Primary Operable Breast Cancer

Prognostic value of a new clinical-genomic model to predict 10-year risk of recurrence in patients with operable breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 530-530
Author(s):  
Lei Lei ◽  
Tzu-Ting Huang ◽  
Andre Ching-Hsuan Chen ◽  
Tzu-Pin Lu ◽  
Skye Hung-Chun Cheng
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Prognostic Model ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Distant Relapse ◽  
Clinical Genomic

530 Background: Searching for a specific biomarker to predict long-term risk of recurrence for all breast cancer subtypes is challenging. DGM-CM6 (Distant Genetic Model-Clinical variable Model 6) is a new clinical-genomic prognostic model developed from the 18-gene panel which was reported previously. This study aims to validate the long-term prognostic value of this new model in all subtypes of operable breast cancer patients. Methods: We included 752 operable breast cancer patients with stage I-III in all subtypes treated in a Cancer Center from 2005 to 2014 as the internal validation (IV) cohort. The median follow-up was 94.1 months. Meanwhile, Affymetrix U133P2 (n = 1139) data obtained from GEO (GSE9195/16391/17907/19615/20711/21653/42568, EMTAB365) were collected as the external validation (EV) dataset. The prognostic effect of DGM-CM6 was then evaluated by uni- and multivariate analyses. The low- and high-risk patients ( < 33 or ≥ 33 as cut-off value) classified by DGM-CM6 were evaluated by the 10-year distant relapse-free interval (DRFI), relapse-free interval (RFI), relapse-free survival (RFS) and distant relapse-free survival (DRFS), respectively. We further compared the predictive performance between DGM-CM6/DGM and PAM50-ROR score in our IV dataset. Results: In the IV dataset, DGM-CM6 was proved to be an independent prognostic factor by multivariate analysis with hazard ratios of 3.1 (1.6-6.0) for RFS (P = 0.0009) and 3.2 (1.6-6.3) for DRFS (P = 0.0009). Significant differences were observed between low- and high-risk groups with 10-year RFI (94.0% vs. 83.5%, P < 0.0001), RFS (90.0% vs. 80.5%, P = 0.0003), DRFI (94.1% vs. 85.0%, P < 0.0001), and DRFS (90.1% vs. 81.9%, P = 0.0004), respectively. The prognostic value of RFS was convinced in the EV dataset (HR = 1.34, P = 0.00052) by the DGM only. According to C-index estimate analysis, DGM appeared to have better performance comparing with PAM50 ROR score in prediction of long-term DR, DRFS, RFI, and RFS in N0 patients (C index for distant recurrence: 0.582 by DGM, 0.528 by ROR). Conclusions: DGM-CM6 could be a new long-term prognostic model to be applied in all subtypes of operable breast cancer patients. Further validation in a large scale of clinical trials is needed.

Correlation between TopIIα and ki-67 expression in tumors of luminal, primary operable breast cancer without HER2/neu overexpression in postmenopausal women as a prognostic factor.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12065-e12065
Author(s):  
Elena P. Ulianova ◽  
Oleg I. Kit ◽  
Vasilij V. Tokmakov ◽  
Iuliana S. Shatova ◽  
Inna A. Novikova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Prognostic Factor ◽  
Postmenopausal Women ◽  
Hormonal Therapy ◽  
Operable Breast Cancer ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Primary Operable Breast Cancer

e12065 Background: Assessment of proliferative activity is important in terms of tumor prognosis. Topoisomerase IIα (TopIIα) and ki-67 are common markers of breast cancer (BC) cell proliferation. The purpose of the study was to assess the correlation between TopIIα and ki-67 expression as a prognostic factor in luminal, primary operable breast cancer without Her 2 neu overexpression in postmenopausal women. Methods: 60 postmenopausal patients with BC (invasive ductal carcinoma) were equally divided into 3 groups: I –luminal A BC, surgical treatment with subsequent radiotherapy and hormonal therapy; II – luminal B BC, surgical treatment with subsequent radiotherapy and hormonal therapy; III – luminal B BC, surgical treatment with subsequent radiotherapy, polychemotherapy and hormonal therapy. Mean age of patients: I – 76.16±3.14 years, II – 65.0±3.91, III – 74.0±2.54 years. Immunohistochemical study was performed with mouse monoclonal ki-67 (Thermo scientific) and TopIIα (Santa Cruz Biotechnology) antibodies using the Reveal Polyvalent HRP-DAB Detection System. Results were analyzed using the STATISTICA 10.0 program (StatSoftInc., USA). Results: The average expression levels of the ki-67 marker in the groups were: I - 12.3±1.4%, II - 15.1±3.1%, III - 37.0±7.1%; TopIIα expression – 3.5±1.6%, 16.0±5.9%, 21.7±6.4%, respectively. The statistically significant Spearman correlation between TopIIα and ki-67 was observed both as general in groups (r = 0.787 at p < 0.001) and in groups with luminal B subtype (groups II and III). Strong positive correlation between TopIIα and ki-67 was registered in groups II (r = 0.941 at p < 0.01) and III (r = 0.864 at p < 0.001) with luminal B subtype. Weak correlation was observed in group I with luminal A subtype (r = 0.477 at p≥0.05). Conclusions: The study revealed a correlative increase in the level of TopIIα with simultaneous overexpression of the ki-67 protein in the studied groups. This indicator can be considered predictive for breast cancer.

Sign in / Sign up

Export Citation Format

Share Document